ArticleFrontiers in pharmacology2026
Hepatoprotective Formula 919 ameliorates hepatic steatosis and metabolic disturbance in NAFLD with involvement of AMPK signaling.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid accumulation and metabolic dysregulation, while effective therapeutic options remain limited. Hepatoprotective Formula 919 (HF919), a traditional Chinese herbal formulation, has shown hepatoprotective effects, but its mechanisms in NAFLD remain incompletely understood. Objective: To evaluate the effects of HF919 on hepatic steatosis and metabolic disturbance in NAFLD and the possible involvement of AMPK-associated metabolic regulation. Methods: Candidate absorbed constituents of HF919 were characterized by UPLC-HRMS and prioritized by Results: HF919 alleviated hepatic steatosis, reduced hepatic lipid accumulation, and improved serum and hepatic lipid-related indices in HFD-induced NAFLD rats. HF919 treatment increased hepatic p-AMPK abundance and Conclusion: HF919 ameliorated hepatic steatosis and metabolic abnormalities in HFD-induced NAFLD rats. The accompanying increase in hepatic p-AMPK abundance and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.